NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors

About this update from Neonc Technologies Holdings, Inc.

Appointment deepens the Board's strategic and financial oversight as the Company advances its NEO platform toward its next phase of growth CALABASAS, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced the appointment of Nasim Shomali to its Board of Directors, effective July 1, 2026. "We are delighted to welcome Nasim to our Board at an important time for NeOnc," said Amir Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc. "Nasim brings a valuable combination of scientific, strategic and financial expertise. She has advised some of the world's largest and most complex organizations on strategy, financial planning and long-term value creation, while her scientific background enables her to engage meaningfully with our clinical programs. As we approach important clinical and regulatory milestones and expand our development efforts internationally, Nasim's judgment and disciplined approach to capital allocation will strengthen our Board and support our mission to build lasting value for patients and shareholders." Ms. Shomali commented, "My career has been built at the intersection of the laboratory and the capital markets, and that is the perspective I hope to bring to the NeOnc Board. The Company is pursuing genuinely novel approaches to reach cancers of the brain and central nervous system that remain among the hardest to treat, and it is doing so with a rigor that shows in both the science and the way the business is being built." She continued, "I am honored to join a Board and management team of this caliber, and I look forward to supporting the team as NeOnc advances its clinical programs and brings these therapies closer to the patients who need them." Ms. Shomali brings more than a decade of experience advising large, complex organizations on corporate strategy, operating models, financial planning, and organizational transformation, grounded in formal training in biomedical engineering and finance. Most recently, she served as a Strategy Executive at Accenture, where she advised Fortune-100 and multinational enterprises across the life sciences, technology, and energy sectors. Her work spanned corporate strategy ...

View stock analysis, news, and events for Neonc Technologies Holdings, Inc.